Health in Macau (China) 294 indicators covering health for Macau (China). IndicatorLatest Year10-yr change Rank People using safely managed drinking water services, urban 100.0% 2024 up 0.0% 1st Physicians 1.56 per 1,000 people 1987 up 46.4% 100th Physicians per 1000 people 1.56 1987 up 46.4% 100th Number of incident tuberculosis cases 420 2024 down 35.4% 139th Incidence of tuberculosis 59 2024 down 44.3% 83rd Tuberculosis deaths by hiv status 2 2024 down 50.0% 134th Tuberculosis case fatality rate 17 2024 down 10.5% 45th Number of incident tuberculosis cases 5 2024 down 54.5% 144th Number of deaths due to tuberculosis, excluding HIV 71 2024 down 40.8% 124th Deaths due to tuberculosis among HIV-negative people 9.9 2024 down 47.9% 60th Incidence of tuberculosis sdgs 59 2024 down 44.3% 84th Tuberculosis deaths region 73 2024 down 39.2% 124th Tuberculosis death rate 10 2024 down 50.0% 67th Tuberculosis deaths who 73 2024 down 39.2% 124th Tuberculosis patients with hiv share 1.1 2024 down 35.3% 136th Tuberculosis - new and relapse cases 276 2024 down 29.9% 146th Tuberculosis treatment coverage 65 2024 up 6.6% 153rd Rubella - number of reported cases 0 2025 down 100.0% 91st Treatment success rate: new TB cases 88 2023 up 7.3% 62nd Yellow fever - number of reported cases 0 2025 — 26th Tuberculosis treatment success rate in new and relapsed cases 88 2023 up 7.3% 68th Terrorism deaths by region 0 2021 — 58th Tb related deaths hiv 1 2023 unchanged 145th Mumps - number of reported cases 57 2025 down 47.7% 67th Incidence of tuberculosis (per 100 000 population) 0.52 2023 down 52.7% 117th Congenital Rubella Syndrome - number of reported cases 0 2025 — 16th Adolescent birth rate 0 2022 — 147th Treatment success rate: previously treated TB cases 100 2022 up 100.0% 1st Cases of paralytic polio from vaccine derived viruses 0 2023 — 24th Cases of paralytic polio from wild vs vaccine derived viruses 0 2023 — 24th TB patients with known HIV status 98.0% 2024 up 8.9% 42nd Confirmed cases of RR-/MDR-TB 10 2024 up 25.0% 127th Tested TB patients HIV-positive 1.1% 2024 down 35.3% 141st New cases tested for RR-/MDR-TB 98.0% 2024 down 2.0% 53rd Previously treated cases tested for RR-/MDR-TB 96.0% 2024 up 21.5% 65th Number of people notified with new episode of TB in a given year 340 2021 down 11.0% 139th Number of people diagnosed with new episode of pulmonary TB who are 37 2021 down 70.6% 135th Number of people diagnosed with new episode of pulmonary TB who have 59 2021 up 28.3% 136th Cases started on MDR-TB treatment 10 2024 up 42.9% 122nd Number of people diagnosed with new episode of pulmonary TB who are 242 2021 up 63.5% 133rd New or unknown treatment history cases: Pulmonary, bacteriologically 230 2023 down 19.6% 138th Life satisfaction vs life expectancy 83.08 2023 up 0.7% 22nd Tb patients tested positive for hiv 4 2021 up 100.0% 131st Estimated number of MDR/RR-TB incident cases 12 2024 down 29.4% 139th Tb patients living with hiv receiving art 3 2021 up 200.0% 117th HIV-positive TB patients on ART (antiretroviral therapy) 100.0% 2024 up 20.5% 1st Treatment success rate for patients treated for MDR-TB 100.0% 2022 up 16.3% 1st Treatment success rate: HIV-positive TB cases 67 2023 down 33.0% 93rd Share of deaths registered 86.93 2019 — 100th Japanese encephalitis - number of reported cases 0 2025 — 19th Import of environmentally sound technologies 131.92 million 2020 up 48.3% 136th Export of environmentally sound technologies 2.03 million 2020 down 69.5% 141st The number of people with susceptibility test result for rifampicin 193 2021 — 95th The number of people with susceptibility test result for rifampicin 98.97 2021 — 34th ← Previous Page 5 of 5